Rosetta Genomics last week published data validating its miRview Mets 2 cancer of unknown primary origin diagnostic.
In a paper published in The Oncologist, company researchers reported that the test could use microRNA signatures to identify 42 tumor types with high accuracy, maintaining the performance across patient samples.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
